Globus Medical Inc. (GMED)

GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.

GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.

Globus Medical, Inc. (NYSE:GMED ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian J. Kearns - Senior Vice President of Business Development & Investor Relations D...

Although the revenue and EPS for Globus Medical (GMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall S...

Globus Medical (GMED) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.75 per share a year ago.

Globus Medical (GMED) Q2 Revenue Up 18%

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Globus Medical (GMED), delve into some of its key metrics to gain a deeper insight into the company's potential performance for ...

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.

Globus Medical shares have reset after a soft Q1 and Nevro acquisition, making valuations more attractive despite near-term dilution. The company's strong growth, driven by NuVasive integration and pr...